BioSim™ anti-Bevacizumab II (Human) ELISA Kit - E4874

E4874 | BioSim™ anti-Bevacizumab II (Human) ELISA Kit DataSheet

Bevacizumab is a humanized IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor A (VEGF-A) and prevents its binding to cell surface receptors. VEGFA is a pro-angiogenic protein that promotes migration, proliferation, and survival of endothelial cells. Binding of the antibody to VEGFA results in decreased neovascularization, thus limiting blood supply to the tumors and ultimately causes shrinkage of the tumor. The antibody is approved to treat advanced stages of cancer such as colorectal cancer, non-small cell lung cancer, metastatic breast cancer, and glioblastoma multiforme. BioSim™ anti-Bevacizumab ELISA kit has been specifically developed to qualitatively determine antibodies to Bevacizumab in human serum and plasma samples. The ELISA kit is based on the sandwich principle. Controls and samples (serum and plasma) are incubated in the microtiter plate coated with the drug Bevacizumab. After incubation, the wells are washed and the enzymatic activity is detected by the addition of chromogen-substrate. The enzyme-substrate reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies specific for Bevacizumab present in the samples and controls. The qualitative test results can be evaluated using cut-off value.

Alternate Name :

Tag Line : A Sandwich ELISA kit for the qualitative measurement of antibodies to Bevacizumab in human serum or plasma samples

Summary :

Detection Method : Absorbance (450 nm)

Sample Type : Plasma,Serum

Species Reactivity : Human

Applications : This Sandwich ELISA kit is used for in vitro qualitative determination of antibodies to Bevacizumab in human serum and plasma samples

Features and Benefits : Assay Precision: Intra-Assay and Inter-Assay CV < 30%,For in vitro qualitative determination of antibodies to Bevacizumab in human serum and plasma samples,Cross Reactivity: Except for Bevacizumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins